Thank you, Anita. Yeah. The sales in Q3 were 144 million. SEK. But I will also highlight that our business is 75% in the US. Hence, the organic growth is the most relevant metric to gauge the overall sales performance in Q3. We saw organic growth decline by 5% compared to the same quarter in 2023. But also, what you see here is that the reported growth is down 8% compared to last year. So the relevant context for this result is that the overall US probiotic market on a volume basis has contracted since the peak during the pandemic. This is according to the leading market research source, Euromonitor. Beyond this, we also saw various timing impacts in Q3. For the other markets. In EMEA, the overall performance was flat compared to last year. That statement actually covers it. B2B has overall very good traction, but B2C was impacted by timing as we are positioning to leverage the new branding in Q4. The growth in the APAC region is negatively impacted by the general economic slowdown in China, and I will cover this a little more in the following slides. For EBITDA, the result is 20% in Q3. This is an improvement of the EBITDA margin by two percentage points against Q3 last year, and we find that quite exciting because, as Anita said, we have seen improvements in our production KPIs. In Q3, we actually see these improvements beginning to flow into the P&L, improving both the gross profit and the EBITDA. Now, examining the regional segments on a year-to-date basis, the Americas, in constant currency, are down 1% compared to last year. I mentioned earlier the relevant context with the contracting market, but we will really focus now. And that's what our sales team is doing: building the pipeline. That's what it's all about. This involves various activities, including our insight team promoting Probi at the major US trade show, SupplySide West in Las Vegas, next week. Here, they will showcase both the new branding and launch the Metabolic health concept specifically for the US. The gross profit margin is down on a year-to-date basis, but very importantly, it was actually up in Q3. So in H1, we saw that gross profit was impacted by the added resources, for example, in operations to facilitate the improvements in production. And the result is exactly what we see now. And we are, as I mentioned, quite excited by this. EMEA sales are up significantly compared to 2023, actually 29% on a year-to-date basis. Most of those improvements are related to low comparisons in 2023. We earlier mentioned that we had to reduce overstocking in a few big accounts in 2023, and now the sales are normalizing. This is a favorable impact. And also in 2023, we experienced a very significant impact from the insourcing of our B2C business. The sales in Q3 are actually at the same level as last year. And as mentioned, this is good news as B2C is reduced to facilitate the new branding in Q4. The high growth in EMEA helps Probi overall to improve profitability. This is because EMEA, as you can tell from the slides, has above-average profitability. So, this is driving the overall profitability for Probi, yet it should be noted that the margin is below last year. Specifically for EMEA, though, there are very specific reasons related to customer and product mix. Now, regarding APAC, sales in Q3 were below expectations and came after similar soft sales in previous quarters. Sales in the APAC region were impacted by a general economic slowdown, specifically in China, and tougher market conditions, which have caused delays in product launches and reduced commercial traction. Probi continued its market activity at a high pace in the region to maintain momentum and foster long-term relationships, but importantly, Probi has maintained its market position and not lost any customers. On the gross margin in Q3, it was up compared to last year. Yet, on a year-to-date basis, it was impacted by an adverse customer mix. The net income for Q3, compared to the same quarter last year, shows that sales volume is down as reported earlier. Organically 5%, which is here quantified as an adverse volume impact of 3.5 million. The gross profit is favorably impacted due to the improved margins in Q3 of 2.4. OpEx has improved, as mentioned in the report, for example through higher capitalization of R&D costs, timing of marketing costs for B2C, and a few other factors. Overall, the impact is 0.5 for the quarter. The financial result is also driven by FX gains and losses for bank accounts and foreign currency. And overall, this means that net income is 4.0 million for the quarter, which compares to 6.4 million last year and hence is 2.4 million down in the quarter. Solid cash generation on a year-to-date basis. Operating cash flow of 85 million for the nine-month period. We continue to invest in Q3, and now, it's at a level of 38 million. Year to date, this CapEx covers both plant and machinery. In our production facilities, we cover not only the machinery and equipment but also the R&D project costs to support the sales pipeline. Financing, by and large, is the least costly aspect related to our main production sites in the US, and as this statement covers year to date, we also include the Q2 dividend payout of 15 million. All in all, resulting in a cash end of period of 349 million. And now I'd like to hand over to Anita.